A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide

NCT07668414 · Not yet recruiting

Last updated 2026-07-13

This study is testing whether the experimental medicine zenagamtide helps people with excess body weight lose weight better than the approved medicine semaglutide.

Status Not yet recruiting Approved but enrollment has not started.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 650 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2026-09 · est. completion 2028-10

Where 46 sites · United States

What this study is testing ClinicalTrials.gov NCT07668414 ↗

Description as written by the study sponsor.

The purpose of this study is to find out if zenagamtide is safe and effective for treating participants who have excess body weight compared to treatment with semaglutide.

Treatments tested

Zenagamtide Drug

Zenagamtide will be administered subcutaneously using pre-filled pen-injectors to one of the body parts: thigh, abdomen or upper arm.
Semaglutide Drug

Semaglutide will be administered subcutaneously using pre-filled pen-injectors to one of the body parts: thigh, abdomen or upper arm.
Placebo (matched to semaglutide) Drug

Placebo matched to semaglutide will be administered subcutaneously using pre-filled pen-injectors to one of the body parts: thigh, abdomen or upper arm.
Placebo (matched to zenagamtide) Drug

Placebo matched to zenagamtide will be administered subcutaneously using pre-filled pen-injectors to one of the body parts: thigh, abdomen or upper arm.

Main thing measured	Relative change in body weight
Sponsor	Novo Nordisk A/S
Conditions studied	Overweight, Obesity
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07668414 ↗